Joincare(SH:600380)2018-04-26 16:00Financial Performance - Operating revenue for the period reached CNY 3,009,285,562.46, representing a year-on-year increase of 9.08%[8] - Net profit attributable to shareholders was CNY 225,798,993.58, up 17.85% from the same period last year[8] - Basic earnings per share increased by 17.77% to CNY 0.1445[8] - Operating profit for the same period was ¥487,289,465.34, up 14.05% from ¥427,359,245.45 year-on-year[33] - Net profit attributable to shareholders of the parent company was ¥225,798,993.58, representing a 17.8% increase from ¥191,591,886.01 in Q1 2017[33] - The total operating costs rose to ¥2,528,401,973.36, an increase of 6.95% compared to ¥2,363,907,710.06 in the previous year[33] Assets and Liabilities - Total assets at the end of the reporting period were CNY 22,160,411,274.29, a decrease of 0.23% compared to the end of the previous year[8] - Current assets totaled CNY 14,106,690,472.08, down from CNY 14,330,523,408.95 at the start of the year, indicating a decrease of approximately 1.56%[27] - The company's cash and cash equivalents decreased to CNY 8,623,499,768.38 from CNY 9,063,239,390.13, reflecting a decline of about 4.84%[27] - Total liabilities decreased to CNY 8,220,759,035.74 from CNY 8,593,735,766.39, representing a reduction of approximately 4.35%[28] - The total equity of the company was reported at ¥2,934,456,355.43, slightly down from ¥2,964,635,149.10, indicating a decrease of about 1%[33] Cash Flow - The net cash flow from operating activities was CNY 322,716,031.95, down 19.93% compared to the previous year[8] - The total cash inflow from operating activities for Q1 2018 was CNY 3,306,799,881.60, an increase of 18.8% compared to CNY 2,783,670,243.19 in the same period last year[36] - The net cash flow from investment activities was negative CNY 365,859,349.37, a significant decline from a positive CNY 511,435,561.08 in the same quarter last year[36] - The net cash flow from financing activities was negative CNY 337,230,936.47, compared to a positive CNY 275,802,797.57 in Q1 2017[36] - The company reported a net cash outflow of CNY 420,266,585.81 for the quarter, contrasting with a net increase of CNY 1,186,262,976.17 in the same period last year[36] Shareholder Information - The total number of shareholders at the end of the reporting period was 131,992[12] - The largest shareholder, Shenzhen Baiye Yuan Investment Co., Ltd., held 742,415,520 shares, accounting for 47.17% of the total shares[12] Investments and Corporate Actions - The company plans to invest USD 10 million to acquire a 10% stake in PANTHEON D, L.P. through its wholly-owned subsidiary Joincare Pharmaceutical Group Industry Co., Ltd.[18] - The company completed the equity structure adjustment of its subsidiary, Lizhu Biotech, in March 2018, changing its shareholder to LIVZON BIOLOGICS HONG KONG LIMITED[18] - The company approved the repurchase and cancellation of 850,000 restricted stocks due to the departure of incentive targets, with a total repurchase cost of CNY 3,336,100[19] - The company’s public offering plan for 2017 has been approved by the China Securities Regulatory Commission, pending written approval documents[19]